GlassScriptPhysician profile
William D Shaw Jr
NPI 1568482651
$7,491.59
in general payments reported to CMS, 2019-2025
61 companies · $913 in 2025
The $913 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $747 · 2021: $586 · 2022: $1,408 · 2023: $1,187 · 2024: $1,261 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.14 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $731.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $681.04 | 2019-2025 | Tepezza, Prolia, Evenity |
| Novo Nordisk INC | $669.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $373.99 | 2019-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.02 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $325.00 | 2019-2025 | |
| Pfizer INC. | $251.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $251.23 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $206.07 | 2019-2025 | Veozah |
| Abbott Laboratories | $205.09 | 2021-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $175.25 | 2023-2025 | Rexulti, Nuedexta |
| Radius Health, INC. | $171.76 | 2019-2024 | Tymlos |
| Sumitomo Pharma America, INC. | $156.43 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $146.77 | 2019-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shaw Jr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.